Skip to main content
Susan (Coleman (Married Name)) Hubbard, MD, Pediatrics, Dallas, TX

SusanJeanne(Coleman (Married Name))HubbardMD

Pediatrics Dallas, TX

Physician

Dr. Hubbard is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Hubbard's full profile

Already have an account?

  • Office

    5470 W Lovers Ln
    Ste 330
    Dallas, TX 75209
    Phone+1 214-956-7337
    Fax+1 469-364-8724

Education & Training

  • University of Texas Southwestern Medical Center
    University of Texas Southwestern Medical CenterResidency, Pediatrics, 1983 - 1984
  • University of Texas Medical Branch Hospitals
    University of Texas Medical Branch HospitalsResidency, Pediatrics, 1981 - 1983
  • McGovern Medical School at UTHealth
    McGovern Medical School at UTHealthClass of 1981

Certifications & Licensure

  • TX State Medical License
    TX State Medical License 1981 - 2026
  • American Board of Pediatrics Pediatrics

Awards, Honors, & Recognition

  • Alpha Omega Alpha 1981
  • Super Doctor SuperDoctors.com
  • Fellow (FAAP) American Academy of Pediatrics

Publications & Presentations

Other

Press Mentions

  • Exelixis Announces U.S. FDA Approval of CABOMETYX® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
    Exelixis Announces U.S. FDA Approval of CABOMETYX® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid CancerSeptember 17th, 2021
  • Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
    Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate UpdateAugust 5th, 2021
  • Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer
    Exelixis and Ipsen Announce Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver CancerJune 28th, 2021
  • Join now to see all

Professional Memberships